Reviewer's report

**Title:** Insulin Use and Persistence in Patients with Type 2 Diabetes Adding Mealtime Insulin to a Basal Regimen: A Retrospective Database Analysis

**Version:** 1  **Date:** 4 October 2010

**Reviewer:** Richard Rubin

**Reviewer's report:**

The question posed by the authors is well defined. The editors should note that the authors recently published a paper (Patient Preference and Adherence 2010; 4:147-156) using the same database and identical methodology. The earlier paper considered a different insulin regimen. The earlier paper is not cited in the current manuscript, but it should be (compulsory).

The methods are appropriate and well described, though the authors should provide readers with a sense of what non-persistence means in terms of the amount of insulin a person should have taken (compulsory). This estimate can not be precise, but as it stands the reader is left without a sense of the clinical implications of the defined non-persistence.

The manuscript adheres to relevant standards for reporting and data deposition, though the authors should provide 95% CI for OR in text and in table 3 (compulsory).

The discussion and conclusions are generally balanced and adequately supported by the data, though the issues noted above must be addressed in these sections and the authors should discuss the clinical relevance of the statistically significant findings they report (compulsory).

The limitations of the work are clearly stated.

The authors do not acknowledge their published paper (noted above).

The title and abstract accurately reflect what the authors found.

The writing is acceptable.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I have received research grant support and consultation fees from Novo Nordisk A/S and from Novo Nordisk Inc. I am also a member of scientific advisory boards from both companies. I have also received research grant support and
consultation fees from Eli Lilly and Company.